Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03069352
Registration number
NCT03069352
Ethics application status
Date submitted
28/02/2017
Date registered
3/03/2017
Titles & IDs
Public title
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Query!
Scientific title
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Query!
Secondary ID [1]
0
0
2016-003900-30
Query!
Secondary ID [2]
0
0
M16-043
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia (AML)
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Venetoclax
Treatment: Drugs - Cytarabine
Experimental: Venetoclax + Low Dose Cytarabine (LDAC) - Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
Placebo comparator: Placebo + LDAC - Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
Treatment: Drugs: Placebo
tablet
Treatment: Drugs: Venetoclax
tablet
Treatment: Drugs: Cytarabine
Subcutaneous injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.
Query!
Timepoint [1]
0
0
From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
Query!
Assessment method [1]
0
0
The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML:
CR: No morphologic evidence of AML and absolute neutrophil count (ANC) = 10³/µL (1,000/µL), platelets = 105/µL (100,000/µL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRi: All criteria as CR except for residual neutropenia \< 10³/µL or thrombocytopenia \< 105/µL. If all criteria for CR are met except RBC transfusion independence, the CRi criteria are met.
Participants who had no IWG disease assessments were considered to be non-responders.
Query!
Timepoint [1]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)
Query!
Assessment method [2]
0
0
The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) at any time point during the study assessed by the investigator.
CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count = 10³/µL, platelets = 105/µL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRh is a derived response based on bone marrow blast and hematology lab values, achieved when the following criteria are met:
* Bone marrow with \< 5% blasts and
* Peripheral blood neutrophil count of \> 0.5 × 10³/µL and
* Peripheral blood platelet count of \> 0.5 × 105/µL and
* A 1 week platelet transfusion-free period prior to the hematology lab collection.
Participants with no disease assessments were considered to be non-responders.
Query!
Timepoint [2]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 2
Query!
Assessment method [3]
0
0
The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) before initiation of Cycle 2, assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML:
CR: No morphologic evidence of AML and absolute neutrophil count = 10³/µL, platelets = 105/µL, red cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRi: All criteria as CR except for residual neutropenia \< 10³/µL or thrombocytopenia \< 105/µL. If all criteria for CR are met except for RBC transfusion independence, CRi criteria are met.
Participants who had no IWG disease assessments were considered to be non-responders.
Query!
Timepoint [3]
0
0
Cycle 1, 28 days
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 2
Query!
Assessment method [4]
0
0
The percentage of participants who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) before initiation of Cycle 2 assessed by the investigator.
CR is defined according to the revised guidelines by the IWG for AML as no morphologic evidence of AML, ANC count = 10³/µL, platelets = 105/µL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRh is a derived response based on bone marrow blast and hematology lab values, achieved when when the following criteria are met:
* Bone marrow with \< 5% blasts and
* Peripheral blood neutrophil count of \> 0.5 × 10³/µL and
* Peripheral blood platelet count of \> 0.5 × 105/µL and
* A 1-week platelet transfusion-free period prior to the hematology lab collection.
Participants with no disease assessments were considered to be non-responders.
Query!
Timepoint [4]
0
0
Cycle 1, 28 days
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Complete Remission
Query!
Assessment method [5]
0
0
The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the International Working Group (IWG) for AML. CR is defined as no morphologic evidence of AML and absolute neutrophil count = 10³/µL, platelets = 105/µL, red blood cell transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
Participants who had no IWG disease assessments were considered to be non-responders.
Query!
Timepoint [5]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [6]
0
0
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a
Query!
Assessment method [6]
0
0
PROMIS Fatigue SF 7a is a seven-item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 7a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from Baseline) indicates improvement in fatigue; the minimum important difference used in this study was 3 points.
Query!
Timepoint [6]
0
0
Baseline and Day 1 of Cycles 3, 5, 7, and 9
Query!
Secondary outcome [7]
0
0
Change From Baseline in Global Health Status / Quality of Life
Query!
Assessment method [7]
0
0
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) consists of a Global Health Status/Quality of Life (GHS/QoL) scale, a Financial Difficulties scale, 5 functional scales (Cognitive, Social, Physical, Emotional, and Role Functioning), and 8 symptom scales/items (Fatigue, Insomnia, Appetite Loss, Pain, Constipation, Diarrhea, Dyspnea, and Nausea and Vomiting).
The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL. A positive change from baseline indicates better quality of life.
Query!
Timepoint [7]
0
0
Baseline and Day 1 of Cycles 3, 5, 7, and 9
Query!
Secondary outcome [8]
0
0
Event-free Survival (EFS)
Query!
Assessment method [8]
0
0
Event-free survival is defined as the time from randomization to the date of progressive disease (PD), confirmed morphologic relapse from CR or CRi, treatment failure (failure to achieve CR, CRi or morphologic leukemia free state (MLFS) after at least 6 cycles of study treatment), or death from any cause, assessed by the investigator according to the modified IWG criteria.
PD:
* \> 50% increase in marrow blasts (minimum 15% increase required if blasts \< 30% at baseline); or persistent marrow blast \> 70% for = 3 months; without at least a 100% improvement in ANC to an absolute level \> 0.5 × 10?/L, and/or platelets to \> 50 × 10?/L non-transfused; or
* 50% increase in peripheral blasts to \> 25 × 10?/L; or
* New extramedullary disease
Participants with no events prior to the cut-off date were censored at their last assessment date; participants with no events prior to post-treatment therapy initiated before the cut-off date were censored on the start date of post-treatment therapy.
Query!
Timepoint [8]
0
0
From randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence
Query!
Assessment method [9]
0
0
The post baseline red blood cell (RBC) transfusion independence rate was calculated as the percentage of participants who achieved RBC transfusion independence post baseline. RBC transfusion independence is defined as a period of at least 56 consecutive days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.
Query!
Timepoint [9]
0
0
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm.
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Post Baseline Platelet Transfusion Independence
Query!
Assessment method [10]
0
0
The post baseline platelet transfusion independence rate was calculated as the percentage of participants who achieved platelet transfusion independence post Baseline. Platelet transfusion independence is defined as a period of at least 56 consecutive days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut--off date, whichever occurred earlier.
Query!
Timepoint [10]
0
0
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm.
Query!
Secondary outcome [11]
0
0
Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
Query!
Assessment method [11]
0
0
The rate of conversion was calculated as the percentage of participants who were post-baseline RBC transfusion independent among participants who had an RBC transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). RBC transfusion independence is defined as a period of at least 56 days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.
Query!
Timepoint [11]
0
0
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm.
Query!
Secondary outcome [12]
0
0
Percentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
Query!
Assessment method [12]
0
0
The rate of conversion was calculated as the percentage of participants who were post-baseline platelet transfusion independent among participants who had a platelet transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). Platelet transfusion independence is defined as a period of at least 56 days with no platelet transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.
Query!
Timepoint [12]
0
0
From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm.
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response
Query!
Assessment method [13]
0
0
The percentage of participants with complete remission or complete remission with incomplete blood count recovery AND minimal residual disease (MRD) as assessed by the investigator. Response was based on the modified IWG response criteria for AML:
CR: No morphologic evidence of AML and ANC = 10³/µL, platelets = 105/µL, red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRi: All criteria as CR except for residual neutropenia \< 10³/µL or thrombocytopenia \< 105/µL. If all criteria for CR are met except RBC transfusion independence, CRi criteria are met.
MRD response (at lowest-point MRD value) was defined as having less than 10-³ residual blasts per leukocyte measured in the bone marrow, per European LeukemiaNet (ELN) recommendations.
Participants who had no disease or MRD assessments were considered to be non-responders.
Query!
Timepoint [13]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response
Query!
Assessment method [14]
0
0
The percentage of participants with complete remission or complete remission with partial hematologic recovery (CRh) AND MRD response as assessed by the investigator.
CR is defined according to the modified IWG response criteria for AML as no morphologic evidence of AML, ANC = 10³/µL, platelets = 105/µL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRh is achieved when the following criteria are met:
* Bone marrow with \< 5% blasts and
* Peripheral blood neutrophil count of \> 0.5 × 10³/µL and
* Peripheral blood platelet count of \> 0.5 × 105/µL and
* A 1 week platelet transfusion-free period prior to the hematology lab collection.
MRD response (at lowest-point MRD value) was defined as less than 10-³ residual blasts per leukocyte measured in the bone marrow, per ELN recommendations.
Participants who had no disease or MRD assessments were considered to be non-responders.
Query!
Timepoint [14]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [15]
0
0
Overall Survival (OS) by Mutation Subgroups
Query!
Assessment method [15]
0
0
Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.
Overall survival was analyzed in participants with the following molecular markers:
* Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation
* FMS (Feline McDonough Sarcoma)-like tyrosine kinase 3 (FLT3) mutation
Query!
Timepoint [15]
0
0
From randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.
Query!
Secondary outcome [16]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup
Query!
Assessment method [16]
0
0
Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML:
CR: No morphologic evidence of AML and ANC = 10³/µL, platelets = 105/µL, RBC transfusion independence, and bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRi: All criteria as CR except for residual neutropenia \< 10³/µL or thrombocytopenia \< 105/µL. If all criteria for CR are met except RBC transfusion independence, CRi criteria is met.
Participants who had no IWG disease assessments were considered to be non-responders.
Response was analyzed in participants with the following mutations:
* Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation
* FMS-like tyrosine kinase 3 (FLT3) mutation
Query!
Timepoint [16]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Secondary outcome [17]
0
0
Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation Subgroup
Query!
Assessment method [17]
0
0
The percentage of participants who achieved a complete remission or complete remission with partial hematologic recovery assessed by the investigator for participants with the following mutations:
* Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation
* FMS-like tyrosine kinase 3 (FLT3) mutation
CR is defined according to the modified IWG criteria for AML as no morphologic evidence of AML, ANC = 10³/µL, platelets = 105/µL, RBC transfusion independence, bone marrow with \< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
CRh is achieved when the following criteria are met:
* Bone marrow with \< 5% blasts and
* Peripheral blood neutrophil count \> 0.5 × 10³/µL and
* Peripheral blood platelet count \> 0.5 × 105/µL and
* A 1 week platelet transfusion-free period prior to hematology lab collection. Participants with no disease assessments were considered non-responders
Query!
Timepoint [17]
0
0
Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.
Query!
Eligibility
Key inclusion criteria
1. Participant must have histological confirmation of acute myeloid leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:
* = 75 years of age OR
* = 18 to 74 years of age and fulfill at least one criteria associated with lack of fitness for intensive induction chemotherapy:
* Eastern Cooperative Oncology Group (ECOG) performance status of 2 - 3
* Cardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction = 50% or chronic stable angina
* Diffusing capacity of the lung for carbon monoxide (DLCO) = 65% or forced expiratory volume in 1 second (FEV1) = 65%
* Creatinine clearance = 30 mL/min to < 45 ml/min
* Moderate hepatic impairment with total bilirubin > 1.5 to = 3.0 × upper limit of normal (ULN)
* Other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment
2. Participant must have an ECOG performance status:
* of 0 to 2 for subjects = 75 years of age OR
* of 0 to 3 for subjects between 18 to 74 years of age
3. Participant must have a projected life expectancy of at least 12 weeks.
4. Participant must have adequate renal function as demonstrated by a creatinine clearance = 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.
5. Participant must have adequate liver function as demonstrated by:
* aspartate aminotransferase (AST) = 3.0 × ULN*
* alanine aminotransferase (ALT) = 3.0 × ULN*
* bilirubin = 1.5 × ULN*
* Subjects who are < 75 years of age may have bilirubin of = 3.0 × ULN
(*Unless considered to be due to leukemic organ involvement.)
6. Female participants must be either postmenopausal defined as:
* Age > 55 years with no menses for 12 or more months without an alternative medical cause.
* Age = 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle-stimulating hormone (FSH) level > 40 IU/L.
OR
* Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
OR
* A woman of childbearing potential (WOCBP) practicing at least one protocol specified method of birth control starting at Study Day 1 through at least 180 days after the last dose of study drug.
7. Male participants who are sexually active, must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug.
8. Females of childbearing potential must have negative results for pregnancy test performed:
* At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
* Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.
* Subjects with borderline pregnancy tests at Screening must have a serum pregnancy test = 3 days later to document continued lack of a positive result.
9. Participant must voluntarily sign and date an informed consent form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for myelodysplastic syndrome is allowed except for use of cytarabine.
2. Participant had an antecedent myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia (CML) with or without BCR-ABL 1 translocation and AML with BCR-ABL 1 translocation.
3. Participants that have acute promyelocytic leukemia (APL).
4. Participant has known central nervous system (CNS) involvement with AML.
5. Participant has known human immunodeficiency virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.
6. Participant is known to be positive for hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals (non-exclusionary medications) are not excluded.
7. Participant has received strong or moderate cytochrome P450 3A4 (CYP3A) inducers 7 days prior to the initiation of study treatment.
* Chinese subjects are excluded from receiving strong and/or moderate CYP3A inhibitors 7 days prior to the initiation of study treatment through the end of intensive pharmacokinetic (PK) collection (24 hours post dose on Cycle 1 Day 10).
8. Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the initiation of study treatment.
9. Participant has cardiovascular disability status of New York Heart Association Class > 2. Class 2 is defined as cardiac disease which subjects are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain. Class 3 is defined as cardiac disease which subjects are comfortable at rest but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4 is defined as cardiac disease which subjects have an inability to carry on any physical activity without discomfort, symptoms of heart failure at rest, and if any physical activity is undertaken then discomfort increases.
10. Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of LDAC that in the opinion of the investigator would adversely affect his/her participating in this study.
11. Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.
12. Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
13. Participant has a history of other malignancies prior to study entry, with the exception of:
* Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
* Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
14. Participant has a white blood cell count > 25 × 10^9/L. (Note: hydroxyurea administration or leukapheresis is permitted to meet this criterion).
15. Previous treatment with venetoclax and/or current participation in any other research study with investigational products.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/05/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
18/07/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
211
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Calvary Mater Newcastle /ID# 160123 - Waratah
Query!
Recruitment hospital [2]
0
0
Westmead Hospital /ID# 160121 - Westmead
Query!
Recruitment hospital [3]
0
0
Alfred Hospital /ID# 160125 - Melbourne
Query!
Recruitment hospital [4]
0
0
Box Hill Hospital /ID# 162920 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3128 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kentucky
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Pennsylvania
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Washington
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Wisconsin
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Buenos Aires
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Cordoba
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Antwerpen
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Bruxelles-Capitale
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Santa Catarina
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Sao Paulo
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Porto Alegre
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Alberta
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Quebec
Query!
Country [16]
0
0
China
Query!
State/province [16]
0
0
Fujian
Query!
Country [17]
0
0
China
Query!
State/province [17]
0
0
Guangdong
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Jiangsu
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Jilin
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Shanghai
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Sichuan
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Tianjin
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Zhejiang
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Jinan
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Wuhan
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Zhengzhou, Henan
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Brno
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Ostrava
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Prague
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Rhone
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Sarthe
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Bayonne
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Pessac
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Vandoeuvre Les Nancy Cedex
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Baden-Wuerttemberg
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Hamburg
Query!
Country [38]
0
0
Greece
Query!
State/province [38]
0
0
Attiki
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Alexandroupolis
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Athens
Query!
Country [41]
0
0
Greece
Query!
State/province [41]
0
0
Patras
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Thessaloniki
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Budapest
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Pecs
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Debrecen
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Gyor
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Kaposvar
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Kecskemét
Query!
Country [49]
0
0
Ireland
Query!
State/province [49]
0
0
Dublin
Query!
Country [50]
0
0
Ireland
Query!
State/province [50]
0
0
Galway
Query!
Country [51]
0
0
Ireland
Query!
State/province [51]
0
0
Limerick
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Fukui
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Gunma
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Ibaraki
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Kyoto
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Miyagi
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Nagasaki
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Osaka
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tokyo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Yamagata
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Akita
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Hidaka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Nagoya
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Shimotsuga
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Busan Gwang Yeogsi
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Daejeon Gwang Yeogsi
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Seoul Teugbyeolsi
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Seoul
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Ciudad De Mexico
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Michoacan
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Nuevo Leon
Query!
Country [73]
0
0
New Zealand
Query!
State/province [73]
0
0
Auckland
Query!
Country [74]
0
0
Norway
Query!
State/province [74]
0
0
Hordaland
Query!
Country [75]
0
0
Norway
Query!
State/province [75]
0
0
Gralum
Query!
Country [76]
0
0
Puerto Rico
Query!
State/province [76]
0
0
San Juan
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Kemerovskaya Oblast
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Nizhegorodskaya Oblast
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Ryazanskaya Oblast
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Moscow
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Samara
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Sankt-peterburg
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Saratov
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
St. Petersburg
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Yaroslavl
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Gauteng
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Valenciana
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taipei
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Kaohsiung
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Birmingham
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Cardiff
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Harrow
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03069352
Query!
Trial related presentations / publications
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clin Drug Investig. 2022 Aug;42(8):657-668. doi: 10.1007/s40261-022-01172-4. Epub 2022 Jul 13. Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8. Erratum In: Blood Cancer J. 2021 Oct 26;11(10):171. doi: 10.1038/s41408-021-00565-6.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
AbbVie Inc.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Query!
Available to whom?
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/52/NCT03069352/Prot_001.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/52/NCT03069352/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03069352